ACHV Achieve Life Sciences, Inc.

NASDAQ
$7.59

Achieve Life Sciences, Inc. (ACHV) is expected to report earnings on November 10, 2026, before the market open. The consensus earnings estimate is a loss of $0.19 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of +15.4% since its last earnings release on August 11, 2026.

Achieve Life Sciences Missed Consensus Estimates
Tuesday, August 11, 2026 · 8:30 AM ET
Earnings Date
3rd Quarter, Sep 2026
Nov 10
Tuesday · 7:00 AM ET
Earnings Whisper
-
vs ($0.19)
Rev est $26.31M
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $7.11

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About Achieve Life Sciences, Inc.

Achieve Life Sciences Inc. is a pharmaceutical company. It develops and commercializes cytisine treatment to help people battling nicotine addiction. The Company's product candidates include Custirsen, Apatorsen and OGX-225. Achieve Life Sciences Inc., formerly known as OncoGenex Pharmaceuticals Inc., is based in Bothell, United States.

Sector

Healthcare

Industry

Drug Manufacturers/Other